NICE issues final guidance for Servier's Protelos and BMS/Otsuka's Abilify
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has issued two pieces of final guidance both of which confirmed the final draft guidance issued in December: on Bristol-Myers Squibb/Otsuka Pharmaceuticals' Abilify (aripiprazole), for treating young people with schizophrenia, and on Servier's Protelos (strontium ranelate) for preventing osteoporotic fractures.